182 citations
,
November 2017 in “Molecular Aspects of Medicine” This review discusses various therapeutic strategies targeting platelet-derived growth factor signaling in diseases like cancer and atherosclerosis, and evaluates existing treatments without presenting new clinical data.
5 citations
,
February 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that in a mouse model of Leigh syndrome, rapamycin alters brain proteome and may extend survival by targeting protein kinase C.
40 citations
,
July 2023 in “Clinical Pharmacology & Therapeutics” This review discusses the progress and challenges of targeted protein degradation therapies, highlighting the increasing number of degraders in cancer clinical trials and the limited diversity in targeted proteins, primarily focusing on those employing CRL4CRBN as the E3 ligase.
8 citations
,
November 2025 in “Journal of Translational Medicine” This review highlights challenges in developing drugs targeting the Wnt/β-Catenin signaling pathway for cancer due to its complexity and essential roles in normal tissue. It explores targeted protein degradation technology as a promising strategy to overcome these challenges, suggesting potential new avenues for drug development.
54 citations
,
January 2023 in “Signal Transduction and Targeted Therapy” This review examines integrins as pharmacological targets, discussing current integrin-based therapies and emphasizing the need to understand integrin mechanisms for successful drug development, without reporting new clinical results.